Literature DB >> 17985339

Rhodanine-based tau aggregation inhibitors in cell models of tauopathy.

Bruno Bulic1, Marcus Pickhardt, Inna Khlistunova, Jacek Biernat, Eva-Maria Mandelkow, Eckhard Mandelkow, Herbert Waldmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17985339     DOI： 10.1002/anie.200704051

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  42 in total

Review 1.  Are tangles as toxic as they look?

Authors:  Tara L Spires-Jones; Katherine J Kopeikina; Robert M Koffie; Alix de Calignon; Bradley T Hyman
Journal:  J Mol Neurosci       Date:  2011-06-03       Impact factor: 3.444

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains.

Authors:  Masahiro Ono; Shun Hayashi; Kenji Matsumura; Hiroyuki Kimura; Yoko Okamoto; Masafumi Ihara; Ryosuke Takahashi; Hiroshi Mori; Hideo Saji
Journal:  ACS Chem Neurosci       Date:  2011-03-21       Impact factor: 4.418

4.  Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening.

Authors:  Alex Crowe; Wenwei Huang; Carlo Ballatore; Ronald L Johnson; Anne-Marie L Hogan; Ruili Huang; Jennifer Wichterman; Joshua McCoy; Donna Huryn; Douglas S Auld; Amos B Smith; James Inglese; John Q Trojanowski; Christopher P Austin; Kurt R Brunden; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2009-08-18       Impact factor: 3.162

Review 5.  Modulation and detection of tau aggregation with small-molecule ligands.

Authors:  Edward Chang; Nicolette S Honson; Bhaswati Bandyopadhyay; Kristen E Funk; Jordan R Jensen; Sohee Kim; Swati Naphade; Jeff Kuret
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

Review 6.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

7.  Inhibition of Tau aggregation by three Aspergillus nidulans secondary metabolites: 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde.

Authors:  Smita R Paranjape; Yi-Ming Chiang; James F Sanchez; Ruth Entwistle; Clay C C Wang; Berl R Oakley; T Chris Gamblin
Journal:  Planta Med       Date:  2014-01-10       Impact factor: 3.352

Review 8.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

Review 9.  Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

Authors:  Jennifer N Rauch; Steven H Olson; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

Review 10.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.